REG - Hikma Pharmaceutical - Notice of Results <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

08/03/2017 16:05

RNS Number : 9119Y
Hikma Pharmaceuticals Plc
08 March 2017
Notice of results
LONDON, UK, 8 March 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing pharmaceuticals company, will announce its preliminary financial results for the year ended 31 December 2016 on Wednesday 15 March2017. 
A presentation and webcast for analysts will be held at 9.30am GMT at Etc. Venues, 155 Bishopsgate, Liverpool St, London, EC2M 3YD. 
To join via conference call please dial: +44 (0) 20 3003 2666
UK Toll Free Number: 0808 109 0700
The results presentation and a webcast recording of the event will be available on the Company's website at www.hikma.com or http://cache.merchantcantos.com/webcast/webcaster/4000/7464/16532/72130/Lobby/default.htm
Playback facility:
A playback of the conference call will be available up to 7 days after the presentation.
UK & International Number: +44 (0) 20 8196 1998
UK Toll-Free Number: 0800 633 8453
Replay PIN code: 1028952#
-ENDS-
Enquiries
Hikma Pharmaceuticals PLC 

Susan Ringdal, VP Corporate Strategy and Investor Relations
+44 (0)20 7399 2760/+44 7776 477050
Lucinda Baker, Deputy Director of Investor Relations
+44 (0)20 7399 2765/+44 7818 060211

FTI Consulting

Ben Atwell/Matthew Cole
+44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and nonbranded generic and inlicensed products. Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa ("MENA") and Europe. In 2015, Hikma achieved revenue of $1,440 million and profit attributable to shareholders of $252 million. For more information visit www.hikma.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NORKMGGFKRLGNZM